VitaSpring Biomedical Co., Ltd. filed its Form 10-Q for the quarterly period ended July 31, 2025. The company is in a development stage, focusing on cell-based technologies for regenerative and preventative health applications, but has not generated revenue in the current or prior periods. As of July 31, 2025, the company had only $799 in cash and a working capital deficit of $4,215,713. The company incurred a net loss of $110,845 for the three months ended July 31, 2025, and $191,386 for the six months ended July 31, 2025. Management has identified a material weakness in internal controls over financial reporting due to insufficient segregation of duties and lack of experienced personnel. The company's ability to continue as a going concern is in doubt due to its financial condition, and management is seeking additional capital through equity financing or strategic partnerships. A significant portion of liabilities consists of unsecured, non-interest-bearing obligations to related parties, with a deferred payment agreement for $2,411,000 in accounts payable to a related party extending for 24 months from May 18, 2026.